Corindus Vascular Robotics, Inc. (CVRS) Analysts See $-0.03 EPS; Atlassian Plc Class A Ord (TEAM) Shorts Lowered By 10.05%

February 15, 2018 - By Vivian Park

Atlassian Corporation Plc Class A Ord (NASDAQ:TEAM) had a decrease of 10.05% in short interest. TEAM’s SI was 6.92 million shares in February as released by FINRA. Its down 10.05% from 7.69M shares previously. With 955,500 avg volume, 7 days are for Atlassian Corporation Plc Class A Ord (NASDAQ:TEAM)’s short sellers to cover TEAM’s short positions. The SI to Atlassian Corporation Plc Class A Ord’s float is 8.46%. The stock increased 0.79% or $0.41 during the last trading session, reaching $52.5. About 19,358 shares traded. Atlassian Corporation Plc (NASDAQ:TEAM) has risen 61.70% since February 15, 2017 and is uptrending. It has outperformed by 45.00% the S&P500.

Analysts expect Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) to report $-0.03 EPS on March, 21.They anticipate $0.05 EPS change or 62.50% from last quarter’s $-0.08 EPS. After having $-0.04 EPS previously, Corindus Vascular Robotics, Inc.’s analysts see -25.00% EPS growth. The stock decreased 1.91% or $0.0176 during the last trading session, reaching $0.9025. About 460,060 shares traded. Corindus Vascular Robotics, Inc. (NYSEAMERICAN:CVRS) has risen 8.65% since February 15, 2017 and is uptrending. It has underperformed by 8.05% the S&P500.




Atlassian Corporation Plc, through its subsidiaries, provides team collaboration and productivity software solutions worldwide. The company has market cap of $12.19 billion. It offers project tracking, content creation and sharing, real-time communication, and service management products to large and small organizations. It currently has negative earnings. The companyÂ’s products include JIRA, a workflow management system that enables teams to plan, organize, track, and manage their work and projects; Confluence, a content collaboration platform that is used to create, share, organize, and discuss projects; HipChat that provides teams a way to communicate in real-time and share ideas, updates, codes, and files; Trello, a Web project management application for capturing and adding structure to fluid and fast-forming work for teams; Bitbucket, a code management and collaboration product for teams using distributed version control systems; and JIRA Service Desk, a service desk product for creating and managing service experiences for various service team providers, including IT help desks, and legal and HR teams.

Among 9 analysts covering Atlassian (NASDAQ:TEAM), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Atlassian had 13 analyst reports since January 4, 2016 according to SRatingsIntel. The firm has “Equal-Weight” rating given on Monday, January 4 by Morgan Stanley. On Friday, August 5 the stock rating was maintained by Canaccord Genuity with “Buy”. UBS maintained Atlassian Corporation Plc (NASDAQ:TEAM) on Friday, October 28 with “Buy” rating. The stock has “Buy” rating by Canaccord Genuity on Monday, January 4. On Thursday, January 5 the stock rating was initiated by BMO Capital Markets with “Market Perform”. The rating was initiated by Pacific Crest on Tuesday, November 15 with “Sector Weight”. Jefferies initiated it with “Buy” rating and $37 target in Monday, January 4 report. The stock of Atlassian Corporation Plc (NASDAQ:TEAM) earned “Mkt Outperform” rating by JMP Securities on Friday, January 29. The firm earned “Mkt Perform” rating on Monday, January 4 by JMP Securities. The stock of Atlassian Corporation Plc (NASDAQ:TEAM) earned “Neutral” rating by Goldman Sachs on Monday, January 4.

Corindus Vascular Robotics, Inc. designs, makes, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures. The company has market cap of $170.30 million. The firm offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. It currently has negative earnings. The Company’s CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise, robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: